Aurobindo Pharma USA will acquire Lannett from Lannett Seller Holdco for $250 million on a cash-free, debt-free basis.

Aurobindo Pharma USA acquires Lannett Company LLC for $250 million, expanding U.S. manufacturing capabilities and product ...

Aurobindo Pharma to acquire US-based Lannett for $250M, gaining a strategic local manufacturing base to offset tariffs and ...

Hyderabad: In a major strategic move, Aurobindo Pharma Limited has announced that its wholly owned subsidiary, Aurobindo ...

The transaction is valued at an enterprise value of $250 million (₹21,850 crore) on a cash-free, debt-free basis, including ...

The deal is being carried out on a cash-free, debt-free basis, factoring in standardised working capital levels.

Hyderabad: Amid rising fears of US President Donald Trump imposing tariffs on Indian pharma imports, Aurobindo Pharma is ...

Aurobindo Pharma Ltd. reported a 10.3 per cent year-on-year (YoY) decline in consolidated net profit to Rs 824.2 crore in Q1 ...

Mumbai:Aurobindo Pharma Limited on Monday reported a 10.2 per cent year-on-year (YoY) drop in consolidated net profit to Rs ...

With the stock currently trading at Rs 1,114.50, Aurobindo Pharma experiences a decline in the early trading session.

Philadelphia, PA - February 1, 2011 - Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic pharmaceuticals, today announced that it recently met with the U.S. Food and Drug Administration ...